Biogen (BIIB) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free BIIB Stock Alerts $218.73 +0.92 (+0.42%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 1:23 AM | markets.businessinsider.comLost Money on Biogen Inc. (BIIB)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyMay 28 at 8:35 PM | businesswire.comBiogen Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Against BIIBMay 28 at 10:08 AM | finance.yahoo.comIs Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals?May 27 at 3:22 PM | marketbeat.comEaton Financial Holdings Company LLC Purchases Shares of 5,062 Biogen Inc. (NASDAQ:BIIB)Eaton Financial Holdings Company LLC bought a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 5,062 shares of the biotechnology company's stock, valued at approximately $1,310,000. Other institutional invMay 27 at 12:48 PM | markets.businessinsider.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the FirmMay 27 at 7:48 AM | finance.yahoo.comThe Biggest Biotechnology Company in EuropeMay 26 at 11:22 AM | markets.businessinsider.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BiogenMay 26 at 1:21 AM | finance.yahoo.comThe Biggest Publicly Traded Biotech CompanyMay 25, 2024 | marketbeat.comRobeco Institutional Asset Management B.V. Sells 180,219 Shares of Biogen Inc. (NASDAQ:BIIB)Robeco Institutional Asset Management B.V. trimmed its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 52.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 161,591 shares of the biotechnology company'May 25, 2024 | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Stock Holdings Raised by Primecap Management Co. CAPrimecap Management Co. CA raised its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 1.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,264,481 shares of the biotechnology compMay 24, 2024 | markets.businessinsider.comBiogen’s Strategic Diversification and Financial Strategy Garner Outperform RatingMay 24, 2024 | americanbankingnews.comBiogen (NASDAQ:BIIB) Earns "Buy" Rating from HC WainwrightMay 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Walgreens Boots Alliance (WBA)May 23, 2024 | prnewswire.comBIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 23, 2024 | businesswire.comKirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) InvestorsMay 23, 2024 | businesswire.comBIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 23, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the FirmMay 23, 2024 | stockhouse.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BiogenMay 23, 2024 | markets.businessinsider.comBiogen’s Buy Rating Bolstered by Strategic Acquisition and Promising Pipeline ExpansionMay 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Biogen on Strategic Acquisition and Promising PipelineMay 23, 2024 | marketbeat.comFranklin Resources Inc. Trims Stock Holdings in Biogen Inc. (NASDAQ:BIIB)Franklin Resources Inc. trimmed its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 20.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 498,349 shares of the biotechnology company's stock afteMay 23, 2024 | marketbeat.comBiogen (NASDAQ:BIIB) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $300.00 price objective on shares of Biogen in a research report on Thursday.May 23, 2024 | businesswire.comBIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 23, 2024 | americanbankingnews.comBiogen (NASDAQ:BIIB) Rating Reiterated by Needham & Company LLCMay 22, 2024 | investopedia.comBiogen Buys Biotech Firm HI-Bio to Boost Its Immunology PortfolioMay 22, 2024 | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIBMay 22, 2024 | bloomberg.comBiogen to Pay Up to $1.8 Billion for Immune Drug DeveloperMay 22, 2024 | finance.yahoo.comBiogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology BiosciencesMay 22, 2024 | markets.businessinsider.comDeep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)May 22, 2024 | finance.yahoo.comBiogen Agrees to Buy Human Immunology Biosciences For up to $1.8 BillionMay 22, 2024 | ca.finance.yahoo.comBiogen in up to $1.8 billion deal as rare diseases take center stageMay 22, 2024 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for Biogen (NASDAQ:BIIB)Needham & Company LLC reissued a "buy" rating and set a $294.00 price objective on shares of Biogen in a research note on Wednesday.May 22, 2024 | marketwatch.comBiogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfrontMay 22, 2024 | reuters.comBiogen to buy Human Immunology Biosciences in up to $1.8 bln dealMay 22, 2024 | globenewswire.comBiogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology BiosciencesMay 22, 2024 | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Shares Sold by Beacon Pointe Advisors LLCBeacon Pointe Advisors LLC reduced its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 75.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,542 shares of the biotechnology company's stock after selling 13,614 shares dMay 21, 2024 | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Holdings Reduced by Beutel Goodman & Co Ltd.Beutel Goodman & Co Ltd. reduced its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 995,456 shares of the biotechnology company's stock after selling 3May 20, 2024 | reuters.comUS FDA approves two biosimilars for blockbuster eye drug EyleaMay 20, 2024 | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Shares Sold by BNP Paribas Asset Management Holding S.A.BNP Paribas Asset Management Holding S.A. trimmed its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 32.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 448,432 shares of the biotechnology company's stock after selling 212,114May 19, 2024 | marketbeat.comPanagora Asset Management Inc. Has $3.98 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB)Panagora Asset Management Inc. lessened its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 87.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,360 shares of the biotechnology company's stock after selliMay 17, 2024 | markets.businessinsider.comIonis, Biogen Down on Ending Development of ALS DrugMay 16, 2024 | markets.businessinsider.comBiogen: A Balanced View Amidst Setbacks and Alzheimer’s Drug PotentialMay 16, 2024 | msn.comBiogen and Ionis Pharma shares slide as they end development of ALS treatmentMay 16, 2024 | msn.comTale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For AnotherMay 16, 2024 | marketbeat.comBiogen (NASDAQ:BIIB) Given "Buy" Rating at Truist FinancialTruist Financial reaffirmed a "buy" rating and set a $340.00 price objective on shares of Biogen in a research report on Thursday.May 16, 2024 | finanznachrichten.deIonis Pharmaceuticals, Inc.: Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisMay 16, 2024 | yahoo.comBiogen, Ionis to discontinue development of experimental ALS drugMay 16, 2024 | marketwatch.comBiogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral SclerosisMay 16, 2024 | finance.yahoo.comREFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drugMay 16, 2024 | marketbeat.comMitsubishi UFJ Asset Management Co. Ltd. Purchases 7,683 Shares of Biogen Inc. (NASDAQ:BIIB)Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 5.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 149,428 shares of the biotechnology company's stock after Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address A once-in-a-century investment opportunity (Ad)It's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more potential than the AI stocks most investors are focused on in the days ahead. To get its name and ticker symbol for free - just click here. BIIB Media Mentions By Week BIIB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIIB News Sentiment▼0.600.85▲Average Medical News Sentiment BIIB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIIB Articles This Week▼4017▲BIIB Articles Average Week Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Teva Pharmaceutical Industries News Today American Electric Power News Today Pinnacle West Capital News Today CRISPR Therapeutics News Today Portland General Electric News Today Denali Therapeutics News Today Vertex Pharmaceuticals News Today Regeneron Pharmaceuticals News Today Gilead Sciences News Today Alnylam Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIIB) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeWARNING about the death of the U.S. dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
